At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 582 enrolled
Drug / intervention
Albaconazole 100mg +4 moredrug
Likely dose
Albaconazole 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Investigate the Efficacy and Safety of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis
In Brief
A Phase 2 clinical trial evaluating Albaconazole 100mg, Albaconazole 200mg, and 2 other interventions for Onychomycosis. Completed, enrolled 582 participants across 33 sites in 3 countries.
Detailed Summary
Phase 2 study to examine how the study drug works and its side effects in subjects with toenail fungus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOnychomycosis
CountriesCanada, Iceland, United States
CollaboratorsGlaxoSmithKline
Timeline
Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2008
First PostedAug 2008
Primary CompletionFeb 2010
TodayJul 2026
First PostedAug 8, 2008
Enrollment StartJul 16, 2008
Primary CompletionFeb 19, 2010
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 17.9 years ago
Interventions
Albaconazole 100mgdrug
Albaconazole for 36 weeks
Albaconazole 200mgdrug
Albaconazole for 36 weeks
Albaconazole 400mgdrug
Albaconazole for 36 weeks
Albaconazole 400mgdrug
Albaconazole for 24 weeks, Placebo for 12 weeks
Placebo 400 mgdrug
Placebo for 36 weeks